Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 78 Neoplasms 69 Prostatic Neoplasms 51 Colorectal Neoplasms 45 Lung Neoplasms 39 Carcinoma, Non-Small-Cell Lung 28 Hematologic Neoplasms 22 Pancreatic Neoplasms 21 Neoplasm Metastasis 20 Head and Neck Neoplasms 20 Urinary Bladder Neoplasms 15 Ovarian Neoplasms 15 Multiple Myeloma 15 Stomach Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 11 Motor Activity 11 Leukemia, Myeloid, Acute 11 Glioblastoma 10 Uterine Cervical Neoplasms 9 Triple Negative Breast Neoplasms 9 Gastrointestinal Neoplasms 9 Colonic Neoplasms 9 Melanoma 8 Hematopoietic and Lymphatic System Neoplasm 8 Glioma 8 Esophageal Neoplasms 8 Carcinoma, Renal Cell 8 COVID-19 8 Anxiety Disorders 8 Anatomic Stage I Breast Cancer AJCC v8 8

Interventions

Peripheral Blood Stem Cell Transplantation 39 fludarabine phosphate 36 Cyclophosphamide 31 Mycophenolic Acid 28 Cyclosporine 25 Whole-Body Irradiation 24 Tacrolimus 22 Busulfan 18 Antilymphocyte Serum 18 Radiotherapy 16 Methotrexate 16 Flow Cytometry 14 Filgrastim 14 Etoposide 13 Methylprednisolone 10 Lenalidomide 10 Bortezomib 10 Vorinostat 9 Melphalan 9 mogamulizumab 8 Therapeutics 8 Rituximab 8 Psychiatric Rehabilitation 8 Polymerase Chain Reaction 8 Gemcitabine 8 Cord Blood Stem Cell Transplantation 7 Bexarotene 7 pembrolizumab 6 Alemtuzumab 6 tanespimycin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sezary Syndrome × Standard of Care × Clear all

NCT05206045 2022-01-25

SURPASSe

Assistance Publique - Hôpitaux de Paris

Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡